PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2021
CASE
AUTH/3471/2/21 Sanofi

Sanofi: complaint about unsolicited Toujeo webinar invitations by email (no breach) | AUTH/3471/2/21

A nurse alleged a Sanofi rep emailed Toujeo Coach webinar invites without consent and said email activity was tracked. Panel found insufficient…

2019
CASE
Sanofi ⭐ Case of the Week

Sanofi breached ABPI Code over unsubstantiated β€œfewer prescriptions” claim for Toujeo DoubleStar in virtual promo meeting

Sanofi’s Toujeo DoubleStar slide deck wrongly claimed β€œfewer prescriptions”. PMCPA ruled the claim misleading and unsubstantiated, and found inadequate rep briefing. No…

2020
CASE
AUTH/3429/11/20 Sanofi

AUTH/3429/11/20: Member of the public v Sanofi β€” medical information call recording and email retention (No breach)

A member of the public alleged GDPR-related issues in Sanofi’s medical information interactions (call recording notice, email retention, and β€œoffline” discussions). The…

2021
CASE
AUTH/3515/5/21 GlaxoSmithKline

GSK webinar registration implied COPD medicines were licensed for asthma; Clause 2 upheld on appeal (AUTH/3515/5/21)

GSK’s severe asthma webinar registration page listed PI links for Trelegy, Anoro and Incruse (COPD-only), implying asthma use. Breaches of Clauses 3.2,…

2021
CASE
AUTH/3508/5/21 Advanz Pharma Services

Advanz Pharma: Macrobid email claim that β€œ1 in 3 adults will fail” trimethoprim for lower UTI ruled misleading (AUTH/3508/5/21)

A GP complaint (via MHRA) about a Macrobid promotional email. PMCPA ruled the β€œ1 in 3 adults will fail treatment with trimethoprim”…

2019
CASE
Novartis Pharmaceuticals UK

Anonymous v Novartis: β€˜Powerful. Proven. Targeted.’ Lucentis strapline ruled ambiguous (breach) in journal ads and HCP webpage

Two ophthalmic journal ads and an HCP webpage used the strapline β€œPowerful. Proven. Targeted.” for Lucentis. PMCPA ruled β€œPowerful” ambiguous (breach), but…

2021
CASE
AUTH/3559/9/21 Sanofi ⭐ Case of the Week

Sanofi: uncertified advocacy planning templates treated as reps’ briefing material (Toujeo) (AUTH/3559/9/21)

Anonymous employee alleged Toujeo/Suliqua β€œadvocate” programme induced prescribing and misused HCP data. Panel found no inducement/GDPR breach, but ruled internal templates were…

2021
CASE
AUTH/3561/9/21 AstraZeneca

AstraZeneca: LinkedIn post and Sunday Times interview found to promote Enhertu for an unlicensed indication (AUTH/3561/9/21)

A senior employee’s LinkedIn post and a Sunday Times interview/press release were ruled promotional, encouraging patient requests and promoting Enhertu in an…

2022
CASE
AUTH/3620/3/22 Strides Pharma UK

Strides Pharma UK: β€˜Suitable for vegetarians’ claim for StritVit D3 ruled misleading (AUTH/3620/3/22)

A StritVit D3 poster claimed β€œsuitable for vegetarians” despite bovine bone gelatin in capsules. PMCPA ruled the claim misleading and found breaches…

2022
CASE
AUTH/3601/1/22 Boehringer Ingelheim

Boehringer Ingelheim: β€˜Unique convenience’ claim in Trajenta digital banner (AUTH/3601/1/22)

Complaint about use of β€˜unique’ in a Trajenta (linagliptin) HCP digital banner claim. Panel ruled no breach of Clause 14.4, accepting the…

2022
CASE
AUTH/3632/4/22 Daiichi-Sankyo UK

AUTH/3632/4/22: Daiichi Sankyo – Lixiana (edoxaban) initiation video on learned society site (No breach)

Complaint alleged a Lixiana initiation β€œwebinar” omitted hepatic monitoring/contraindications and included a dosing interaction error. Panel found no breach as content was…

2022
CASE
AUTH/3635/4/22 Novartis Pharmaceuticals UK ⭐ Case of the Week

Novartis Entresto podcast: unsubstantiated β€˜energy’ claim, β€˜best’ implied superiority, and renal safety downplayed (AUTH/3635/4/22)

PMCPA found Novartis breached the ABPI Code over an Entresto nurse podcast: an unsubstantiated β€˜energy’ claim, β€˜best’ implying superiority, and unqualified renal…

2022
CASE
AUTH/3669/6/22 Small Pharma

Small Pharma website: pipeline content and unclear audience separation led to high standards breach (AUTH/3669/6/22)

Small Pharma’s open-access website discussed psychedelic pipeline programmes using strong, unqualified language without clearly identifying the intended audience. PMCPA ruled a breach…

2022
CASE
AUTH/3696/10/22 SOBI

AUTH/3696/10/22: Complainant v SOBI β€” Guardian sponsored corporate article (No breach)

Anonymous complaint alleged a Guardian-sponsored SOBI corporate article was disguised promotion and misleading. PMCPA Panel ruled no breach of Clauses 3.6, 5.1,…

2021
CASE
Novartis Pharmaceuticals UK

Novartis breached ABPI Code over Jakavi webpage claim implying statistically significant survival benefit vs BAT

PMCPA found Novartis’ Jakavi HCP webpage claim β€œImproved survival benefit compared with BAT” misleading and unsubstantiated because it implied statistically significant survival…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training